Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1412)	2/28/2003 12:03:56 PM
From: jayhawk969	Read Replies (1) \| Respond to of 1475

Wilder, I see a silver lining, this should help in the termination of existing lease agreements that are not insignificant. At a 3MM cap this is potentially a good bet. I am willing to bet on the technology, my concern is what might happen to the shareholder. I am not as well schooled in that area as I would like to be. I bought at 30 Cents and am tempted to add. Looking for some of the expert opinions from our bio-community. J.D.

To: keokalani'nui who wrote (1412)	2/28/2003 1:27:15 PM
From: scaram(o)uche	Respond to of 1475

>> If I had any confidence in what is the truth about x507 << LFA3tip rejected for approval in Europe. That's a strong indication that, even if tested at low doses, cumulative cell depletion might be a concern. Until now, I'd given the advantage to LFA3tip (x507 surrogate?) over anti-CD11a, but...... Raptiva "go" for FDA review and amevive rejected in Europe...... it would be luck, not skill, but MEDI may be making the correct decision. The jerk may come out smelling like a rose. I wouldn't make a move to invest in BTRN now, based on x507. Instead, I'd focus on the value of the Immerge fraction and any downside cushion??? Haven't looked at them in a long time, so..... grain of salt. Eligix....... amazing. Incredible. Called real-time.